FCF Biotech Venture Capital Monitor – USA 02/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 02/2022”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of February 2022, we identify the following current VC trends in the US-Biotech sector:

  • In 2022, overall Biotech funding in the USA has reached USD 7,111m
  • Top 5 deals exceed USD 180m each, largest transaction amounted to USD 3,000m in Altos Labs
  • RA Capital Management (USA) leads the Top 5 Investors (by deal volume), followed by OrbiMed (USA) and Catalio Capital Management (USA)
  • Central Nervous System dominates as the top indication

To access the full report, please click here.

By Dr. Mathias Schott and Sebastian Sommer